Top

Published in:

Open Access 01-12-2018 | Research article

Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis

Authors: Asieh Mansour, Maryam Aboeerad, Mostafa Qorbani, Amir Pejman Hashemi Taheri, Mohamad Pajouhi, Abbas Ali Keshtkar, Bagher Larijani, Mohammad Reza Mohajeri-Tehrani, Mohammad Reza Ganji

Published in: BMC Nephrology | Issue 1/2018

Abstract

Background

Nephrolithiasis is a risk factor for Osteopenia and osteoporosis. Receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin (OPG) regulate bone remodeling and osteoclastogenesis. This study aimed to evaluate the relation between serum OPG, RANKL concentration, and bone mineral density (BMD) in patients with kidney stone disease.

Methods

Forty-four nephrolithiasis patients with either low bone mass or normal BMD (considered control group) were enrolled in this study. BMD was measured at lumbar spine (L1-L4) and femoral neck by dual-energy X-ray absorptiometry (DEXA). The serum OPG and RANKL were determined using the ELISA method.

Results

The median levels of serum OPG were significantly higher in nephrolithiasis patients with low bone mass compared to the nephrolithiasis patients with normal BMD (3.9 pmol/l versus 3.1 pmol/l; P = 0.03), respectively. Negative correlation was detected between bone densities of femoral neck and OPG in patients with nephrolithiasis (r = −.0344, P = 0.02).

Conclusion

The present study showed that high serum fasting OPG levels may be indicative of femoral neck BMD in patients with nephrolithiasis.

Sakhaee K, Maalouf NM, Kumar R, Pasch A, Moe OW. Nephrolithiasis-associated bone disease: pathogenesis and treatment options. Kidney Int. 2011;79(4):393–403.CrossRefPubMed

Lauderdale DS, Thisted RA, Wen M, Favus MJ. Bone mineral density and fracture among prevalent kidney stone cases in the third National Health and nutrition examination survey. J Bone Miner Res. 2001;16(10):1893–8.CrossRefPubMed

Melton LJ, Crowson CS, Khosla S, Wilson DM, O'Fallon WM. Fracture risk among patients with urolithiasis: a population-based cohort study. Kidney Int. 1998;53(2):459–64.CrossRefPubMed

Santos A, Lima EM, Oliveira EA. Bone disease and cytokines in idiopathic hypercalciuria: a review. J Pediatr Endocrinol Metab. 2011;24(7–8):405–10.PubMed

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M-S, Lüthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.CrossRefPubMed

Väänänen K. Mechanism of osteoclast mediated bone resorption—rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005;57(7):959–71.CrossRefPubMed

Bezerra M, Carvalho J, Prokopowitsch A, Pereira R. RANK, RANKL and osteoprotegerin in arthritic bone loss. Braz J Med Biol Res. 2005;38(2):161–70.CrossRefPubMed

Sasso GRS, Florencio-Silva R, Simões RS, Baracat MCP, Soares Júnior JM, Baracat EC. Elevated serum osteoprotegerin levels in women: friend or foe? Revista da Associação Médica Brasileira. 2015;61(6):524–9.CrossRefPubMed

Lucato P, Trevisan C, Stubbs B, Zanforlini B, Solmi M, Luchini C, et al. Nephrolithiasis, bone mineral density, osteoporosis, and fractures: a systematic review and comparative meta-analysis. Osteoporos Int. 2016:1–10.

10.

Trinchieri A. Bone mineral content in calcium renal stone formers. Urol Res. 2005;33(4):247–53.CrossRefPubMed

11.

Tsao KC, Wu TL, Chang PY, Sun CF, Wu LL, Wu JT. Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal. 2007;21(6):426–31.CrossRefPubMed

12.

Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010;55(19):2049–61.CrossRefPubMed

13.

Rasmussen LM, Tarnow L, Hansen TK, Parving H-H, Flyvbjerg A. Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients. Eur J Endocrinol. 2006;154(1):75–81.CrossRefPubMed

14.

Grigorie D, Neacşu E, Marinescu M, Popa O. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. Romanian journal of internal medicine= revue roumaine de. Med Int. 2002;41(4):409–15.

15.

Bushinsky DA. Nephrolithiasis: site of the initial solid phase. J Clin Invest. 2003;111(5):602–5.CrossRefPubMedPubMedCentral

16.

Gomes SA, dos Reis LM, Noronha IL, Jorgetti V, Heilberg IP. RANKL is a mediator of bone resorption in idiopathic hypercalciuria. Clin J Am Soc Nephrol : CJASN. 2008 Sep;3(5):1446–52. PubMed PMID: 18480302. Pubmed Central PMCID: Pmc2518782. Epub 2008/05/16. Eng.

17.

Eastell R, Mosekilde L, Hodgson SF, Riggs BL. Proportion of human vertebral body bone that is cancellous. J Bone Miner Res. 1990;5(12):1237–41.CrossRefPubMed

18.

Lundeen G, Knecht S, Vajda E, Bloebaum R, Hofmann A. The contribution of cortical and cancellous bone to dual-energy X-ray absorptiometry measurements in the female proximal femur. Osteoporos Int. 2001;12(3):192–8.CrossRefPubMed

19.

Martin R, Ishida J. The relative effects of collagen fiber orientation, porosity, density, and mineralization on bone strength. J Biomech. 1989;22(5):419–26.CrossRefPubMed

20.

Lewiecki EM, Miller PD. Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk. J Clin Densitom. 2013;16(1):28–32.CrossRefPubMed

21.

Nickolas TL, Stein EM, Dworakowski E, Nishiyama KK, Komandah-Kosseh M, Zhang CA, et al. Rapid cortical bone loss in patients with chronic kidney disease. J Bone Miner Res. 2013;28(8):1811–20.CrossRefPubMedPubMedCentral

22.

Kim CS, Bae EH, Ma SK, Han SH, Choi KH, Lee J, et al. Association of Serum Osteoprotegerin Levels with bone loss in chronic kidney disease: insights from the KNOW-CKD study. PLoS One. 2016;11(11):e0166792.CrossRefPubMedPubMedCentral

23.

Riggs BL, Melton LJ, Robb RA, Camp JJ, Atkinson EJ, McDaniel L, et al. A population-based assessment of rates of bone loss at multiple skeletal sites: evidence for substantial trabecular bone loss in young adult women and men. J Bone Miner Res. 2008;23(2):205–14.CrossRefPubMed

Title: Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis
Authors: Asieh Mansour
Maryam Aboeerad
Mostafa Qorbani
Amir Pejman Hashemi Taheri
Mohamad Pajouhi
Abbas Ali Keshtkar
Bagher Larijani
Mohammad Reza Mohajeri-Tehrani
Mohammad Reza Ganji
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Nephrology / Issue 1/2018
Electronic ISSN: 1471-2369
DOI: https://doi.org/10.1186/s12882-018-0960-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis

Abstract

Background

Methods

Results

Conclusion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Expression of brain-derived neurotrophic factor in kidneys from normal and cyclosporine-treated rats

Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report

Early renal damage among children living in the region of highest burden of chronic kidney disease of unknown etiology (CKDu) in Sri Lanka

Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study

Atypical cause of intractable diarrhea in a hemodialysis patient, masked by Clostridium difficile-associated diarrhea and ischemic colitis: a case report

Increased risk of deep vein thrombosis in end-stage renal disease patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page